Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01896973 · ClinicalTrials.gov registry record · NA
Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (US)
A NA study, sponsored by HistoSonics.
- Terminated
- Registry status
- NA
- Development phase
- 28
- Enrollment target
NCT01896973 is a NA study that was terminated before completion, run by HistoSonics. The registered enrollment target is 28 participants.
The verdict
NCT01896973, a NA study, was terminated before completion, sponsored by HistoSonics.
- TERMINATED
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
Study Summary
The HistoSonics' Histotripsy BPH Device, the Vortx Rx, is a portable ultrasound therapy device. The purpose of this study is to assess and monitor the performance of the Vortx Rx for initial safety and efficacy for the treatment of Benign Prostatic Hyperplasia.
Interventions
- DEVICE Vortx Rx - Histotripsy BPH Device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2013-07 |
| Est. Completion | 2016-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01896973
The ClinicalTrials.gov registry entry for NCT01896973 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HistoSonics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vortx Rx - Histotripsy BPH Device is the first listed.
NCT01896973 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01896973 about?
NCT01896973 is a clinical study titled "Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (US)". The HistoSonics' Histotripsy BPH Device, the Vortx Rx, is a portable ultrasound therapy device. The purpose of this study is to assess and monitor the performance of the Vortx Rx for initial safety and efficacy for the treatment of Benign Prostatic Hyperplasia.
What is the current status of trial NCT01896973?
This trial is currently terminated. It is a NA study. The enrollment target is 28 participants. The study started on 2013-07. Estimated completion is 2016-12.
What interventions are being tested in trial NCT01896973?
The interventions under investigation include: Vortx Rx - Histotripsy BPH Device (DEVICE).
Who is sponsoring clinical trial NCT01896973?
This trial is sponsored by HistoSonics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.